(4R)-2,2,4,5-tetramethylhexan-3-one

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (4R)-2,2,4,5-tetramethylhexan-3-one
• 化学式: C₁₀H₂₀O
• 分子量: 156.26
• InChiKey: AYGMAUFUPIHQQG-MRVPVSSYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• Hepatitis C Virus Inhibitors
  申请人：Bristol-Myers Squibb Company

  公开号：US20150023913A1

  公开（公告）日：2015-01-22

  The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

  本公开涉及抗病毒化合物，更具体地涉及能够抑制由丙型肝炎病毒（HCV）编码的NS5A蛋白功能的化合物组合，包括这种组合的组成物，以及抑制NS5A蛋白功能的方法。
• TUBULYSIN COMPOUNDS AND CONJUGATES THEREOF
  申请人：Mersana Therapeutics, Inc.

  公开号：US20160022829A1

  公开（公告）日：2016-01-28

  A tubulysin compound conjugate is provided herein. The conjugate comprises a protein based recognition-molecule (PBRM) and a polymeric carrier substituted with one or more -L D -D, the protein based recognition-molecule being connected to the polymeric carrier by L P . Each occurrence of D is independently a tubulysin compound having a molecular weight≦5 kDa. L D and L P are distinct linkers connecting the tubulysin compound and PBRM to the polymeric carrier respectively. Also disclosed are polymeric scaffolds useful for conjugating with a PBRM to form a polymer-tubulysin compound-PBRM conjugate described herein, compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions.

  本文提供了一种管芽菌素化合物结合物。该结合物包括一种基于蛋白质的识别分子（PBRM）和一种聚合物载体，该聚合物载体被取代了一个或多个-LD-D，其中，基于蛋白质的识别分子通过LP连接到聚合物载体上。每个D的出现独立地是分子量≦5 kDa的管芽菌素化合物。LD和LP是连接管芽菌素化合物和PBRM分别到聚合物载体的不同连接物。还公开了用于与PBRM结合形成聚合物-管芽菌素化合物-PBRM结合物的聚合物支架，包括结合物的组合物，其制备方法以及使用结合物或其组合物治疗各种疾病的方法。
• Combinations of Hepatitis C Virus Inhibitors
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20160158200A1

  公开（公告）日：2016-06-09

  The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

  本公开涉及抗病毒化合物，更具体地涉及能够抑制丙型肝炎病毒（HCV）编码的NS5A蛋白功能的化合物组合，包含这种组合的组合物，以及抑制NS5A蛋白功能的方法。
• US9770439B2
  申请人：——

  公开号：US9770439B2

  公开（公告）日：2017-09-26